Related references
Note: Only part of the references are listed.Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma
Isabelle Ollivier-Hourmand et al.
JOURNAL OF HEPATOLOGY (2022)
Baveno VII - Renewing consensus in portal hypertension
Roberto de Franchis et al.
JOURNAL OF HEPATOLOGY (2022)
Immunotherapies for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
Lukas Mueller et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2022)
Emerging immunotherapy or HCC: A guide for hepatologists
Friedrich Foerster et al.
HEPATOLOGY (2022)
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Claudia Angela Maria Fulgenzi et al.
EUROPEAN JOURNAL OF CANCER (2022)
Global burden of primary liver cancer in 2020 and predictions to 2040
Harriet Rumgay et al.
JOURNAL OF HEPATOLOGY (2022)
Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC
Lukas Mueller et al.
EUROPEAN RADIOLOGY (2022)
Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma
Isabelle Ollivier-Hourmand et al.
JOURNAL OF HEPATOLOGY (2022)
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The Current Landscape of Clinical Trials for Systemic Treatment of HCC
Friedrich Foerster et al.
CANCERS (2021)
Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses horizontal ellipsis
Manon Allaire et al.
LIVER INTERNATIONAL (2021)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Fully Automatic Volume Measurement of the Spleen at CT Using Deep Learning
Gabriel E. Humpire-Mamani et al.
RADIOLOGY-ARTIFICIAL INTELLIGENCE (2020)
Virtual Hepatic Venous Pressure Gradient with CT Angiography (CHESS 1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension
Xiaolong Qi et al.
RADIOLOGY (2019)
Non-invasive score using non-contrast-enhanced MRI for identification of clinically significant portal hypertension (CHESS1802): a prospective, multicentre study
Yanna Liu et al.
LANCET (2019)
Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma
Jin Woo Choi et al.
EUROPEAN RADIOLOGY (2018)
Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization
Nam Hee Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The Best Single Measurement for Assessing Splenomegaly in Patients with Cirrhotic Liver Morphology
Zachary Nuffer et al.
ACADEMIC RADIOLOGY (2017)
Non-invasive prediction of portal pressures using CT and MRI in chronic liver disease
Shingo Kihira et al.
ABDOMINAL RADIOLOGY (2016)
Portal Hypertension and the Outcome of Surgery for Hepatocellular Carcinoma in Compensated Cirrhosis: A Systematic Review and Meta-analysis
Annalisa Berzigotti et al.
HEPATOLOGY (2015)
Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma
Pouya Iranmanesh et al.
JOURNAL OF HEPATOLOGY (2014)
Assessing Splenomegaly: Automated Volumetric Analysis of the Spleen
Marius George Linguraru et al.
ACADEMIC RADIOLOGY (2013)
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study
M. Pinter et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Letter: sorafenib in portal hypertension
B. Procopet et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study
Hisashi Hidaka et al.
JOURNAL OF GASTROENTEROLOGY (2012)
Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials
Ping Fang et al.
PLOS ONE (2012)
Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib
Romain Coriat et al.
PLOS ONE (2011)
Beneficial Effects of Sorafenib on Splanchnic, Intrahepatic, and Portocollateral Circulations in Portal Hypertensive and Cirrhotic Rats
Marc Mejias et al.
HEPATOLOGY (2009)
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats
Thomas Reiberger et al.
JOURNAL OF HEPATOLOGY (2009)
The clinical use of HVPG measurements in chronic liver disease
Jaime Bosch et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2009)
Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma
Takeaki Ishizawa et al.
GASTROENTEROLOGY (2008)